Yumanity Therapeutics Inc

+0.03 (+2.70%)
Earnings Announcements

Yumanity Therapeutics Reports Full-Year 2021 Financial Results

Published: 03/24/2022 21:25 GMT
Yumanity Therapeutics Inc (YMTX) - Yumanity Therapeutics Reports Full-year 2021 Financial Results and Recent Corporate Developments.
Yumanity Therapeutics Inc- As of December 31, 2021, Cash, Cash Equivalents and Investments Were $36.5 Million.
Yumanity Therapeutics- Believes Cash, Cash Equivalents, Marketable Securities to Not Be Sufficient to Fund Operating Expenses, Capex Requirements for 12 Months.
Revenue is expected to be $2.5 Million
Adjusted EPS is expected to be -$0.99

Next Quarter Revenue Guidance is expected to be $2.5 Million
Next Quarter EPS Guidance is expected to be -$1.08

More details on our Analysts Page.